logo

Eyegate Pharmaceuticals Inc (EYEG)



Trade EYEG now with
  Date
  Headline
2/5/2018 8:35:36 AM EyeGate Reports Top-Line Results For Phase 2b Trial Of EGP-437 In Cataract Surgery
1/4/2018 8:33:41 AM EyeGate Pharmaceuticals Says Promotes Sarah Romano To CFO, Effective Jan. 1
11/14/2017 8:10:16 AM EyeGate Pharma Q3 Net Loss Widens To $4.1 Mln From $3.4 Mln Last Year
11/1/2017 8:39:42 AM EyeGate Appoints Mike Garanzini As Chief Commercial Officer
9/11/2017 6:34:30 AM EyeGate Launches Social Media Pages To Enhance Investor And Trade Relationships
8/7/2017 7:36:33 AM EyeGate Pharma Q2 Net Loss $3.3 Mln Vs Loss $3.8 Mln Last Year
8/1/2017 7:35:17 AM EyeGate Pharma Enrolls First Patient In Phase 2b Clinical Study Of EGP-437 For Cataract Surgery
6/9/2017 7:04:35 AM EyeGate Pharma Prices Public Offering Of 6.67 Mln Shares Of Common Stock And Warrants For Gross Proceeds Of $10 Mln
5/8/2017 8:37:04 AM EyeGate Q1 Net Loss $2.9 Mln Vs. Loss $2.4 Mln Prior Year
3/13/2017 7:38:23 AM EyeGate Appoints Daniel Durrie And Randall Olson To Its Scientific Advisory Board
2/21/2017 7:38:04 AM Valeant, EyeGate Enter Exclusive, Worldwide Licensing Agreement